Sebastian S.
- Country
- Germany
- Department
- 4. Medizinische Klinik
Research Overview
- Phase II Study of Imetelstat Sodium in High‑Risk MDS and AML Patients Refractory to Hypomethylating Agent Therapy
- Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial
- Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
Data & Insights
Has run more than one trial at 35 of 228 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with particular focus on high-risk disease variants and treatment-resistant cases.
- Advanced AML Treatment Approaches
- High-risk MDS Management
- Stem Cell Transplantation Integration
Their work encompasses innovative therapeutic strategies for patients who have failed conventional treatments.
Novel Therapeutic Applications
The investigator focuses on developing treatment protocols incorporating intensive chemotherapy regimens and targeted molecular therapies for hematologic disorders.
- Combination Therapy Approaches
- Treatment-Resistant Disease
- Therapeutic Innovation
Their expertise extends to evaluating novel agents for patients who have failed hypomethylating agent-based treatments.
Lymphoma Studies
The investigator has significant involvement in treating advanced-stage Hodgkin lymphoma, with emphasis on optimizing treatment protocols and reducing therapy-related complications.
- Treatment Protocol Optimization
- Toxicity Reduction Strategies
- Progressive Disease Management
Their work includes evaluation of modified treatment regimens aimed at improving patient outcomes while minimizing side effects.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.